A collection of publications and data presentations relevant to Reata's development programs
Presentation of Results from the MOXIe Part 2 Study, by Dr. David Lynch
Part 2 of MOXIe was an international, multi-center, double-blind, placebo-controlled Phase 2 trial of omaveloxolone in patients with Friedreich’s ataxia.
We use cookies to offer you a better browsing experience, analyze site usage, and improve the website. By clicking “Accept Cookies”, you expressly agree to our use of cookies in accordance with the use of cookies section of our Privacy Notice. If you wish to prevent our use of cookies, you can opt-out below.